Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche/GSK Boniva Once-Monthly To Be Launched In April

This article was originally published in The Pink Sheet Daily

Executive Summary

The companies are planning "substantial" DTC ad campaigns, Roche says. FDA approves supplemental NDA for once-monthly ibandronate for treatment of osteoporosis in postmenopausal women. Boniva will be priced competitively to the currently marketed bisphosphonates, Roche says.

You may also be interested in...



Bisphosphonate Marketers Push Dosing Advantages After Feb. 6 Fosamax Patent Expiry

Branded osteoporosis drug makers gird for a hit from launch of a low-cost version of Merck’s market leading alendronate.

Bisphosphonate Marketers Push Dosing Advantages After Feb. 6 Fosamax Patent Expiry

Branded osteoporosis drug makers gird for a hit from launch of a low-cost version of Merck’s market leading alendronate.

Roche Plans Boniva Ad Changes To Energize “Static” Script Growth

Swiss drug maker’s new strategy for the osteoporosis therapy will include Fosamax comparison data, new spokesperson.

Related Content

Topics

UsernamePublicRestriction

Register

ID1132356

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel